FDA Rejects Long-Acting Version of Copaxone by Viatris and Mapi Pharma

Monday, 11 March 2024, 13:43

The FDA has declined to approve the long-acting version of Teva's Copaxone developed by Viatris and Mapi Pharma. This decision has implications for the MS drug market and the future of glatiramer acetate therapies. Financial stakeholders are closely watching the developments following this significant setback.

https://store.livarava.com/8cbc86f6-e02c-11ee-9662-5254a2021b2b.jpe — FDA Rejects Long-Acting Version of Copaxone by Viatris and Mapi Pharma

FDA Rejects Long-Acting Version of Copaxone

Viatris (VTRS) announced that the FDA has declined to approve the long-acting version of Copaxone, a key drug in the MS treatment landscape. Mapi Pharma's collaboration with Viatris on this product faced a setback with this decision. The MS community is eagerly awaiting further updates on the status of this innovative therapy.

This article was prepared using information from open sources in accordance with the principles of Ethical Policy. The editorial team is not responsible for absolute accuracy, as it relies on data from the sources referenced.